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Obesity-related leptin resistance manifests in loss
of leptin’s ability to reduce appetite and increase
energy expenditure. Obesity is also associated with
increased activity of the endocannabinoid system,
and CB1 receptor (CB1R) inverse agonists reduce
body weight and the associated metabolic compli-
cations, although adverse neuropsychiatric effects
halted their therapeutic development. Here we
show that in mice with diet-induced obesity (DIO),
the peripherally restricted CB1R inverse agonist
JD5037 is equieffective with its brain-penetrant
parent compound in reducing appetite, body weight,
hepatic steatosis, and insulin resistance, even
though it does not occupy central CB1R or induce
related behaviors. Appetite and weight reduction by
JD5037 are mediated by resensitizing DIO mice to
endogenous leptin through reversing the hyperlepti-
nemia by decreasing leptin expression and secretion
by adipocytes and increasing leptin clearance via
the kidney. Thus, inverse agonism at peripheral
CB1R not only improves cardiometabolic risk in
obesity but has antiobesity effects by reversing lep-
tin resistance.
INTRODUCTION
Endocannabinoids are lipid mediators that elicit a broad range of
effects via G protein-coupled CB1 and CB2 receptors (Pacher
et al., 2006). Activation of CB1R promotes food intake (Di Marzo
et al., 2001), increases lipogenesis in adipose tissue (Cota et al.,
2003; Matias et al., 2006) and liver (Osei-Hyiaman et al., 2005),
and causes insulin resistance (Eckardt et al., 2009; Liu et al.,
2012) and dyslipidemia (Ruby et al., 2008), which suggests
that the endocannabinoid/CB1R system (ECS) is involved in
obesity and its metabolic complications. Indeed, the ECS is
overactive in obesity (Matias et al., 2006), and CB1R inverseCelagonists reduce body weight and improve metabolic abnormal-
ities in obese subjects (Addy et al., 2008; Despres et al., 2005),
although adverse neuropsychiatric effects halted their thera-
peutic development.
We reported that a CB1R neutral antagonist with reduced
brain penetrance, AM6545, was equieffective with its parent
compound rimonabant in reversing hepatic steatosis in diet-
induced obesity (DIO), but was less effective than rimonabant
in reducing bodyweight, adiposity, insulin resistance, and hyper-
leptinemia, and had minimal effect on food intake (Tam et al.,
2010). As rimonabant is both brain penetrant and a CB1R inverse
agonist, its greater efficacy could be due to either its central
action or its inverse agonist properties. The present findings
unequivocally prove the latter through the use of the peripherally
restricted CB1R inverse agonist JD5037, which robustly reduces
food intake, body weight, and adiposity in the absence of brain
CB1R occupancy, as documented by positron emission tomog-
raphy (PET).
Obesity is accompanied by resistance to the anorexic and
weight-reducing effects of leptin (Dardeno et al., 2010), linked
to a defect in leptin signaling, as reflected in decreased phos-
phorylation of the signaling protein STAT3 in the arcuate
nucleus (Myers et al., 2010). Hyperleptinemia plays a key role
in leptin resistance (Knight et al., 2010), and leptin sensitivity
is restored when plasma leptin is reduced following dietary
weight loss (Enriori et al., 2007). Chronic CB1R blockade atten-
uates hyperleptinemia in obese subjects (Despres et al., 2005)
and rodents (Ravinet Trillou et al., 2003; Tam et al., 2010), and
CB1R
/mice exhibit increased leptin sensitivity (Ravinet Trillou
et al., 2004). This suggests that reversal of leptin resistance
contributes to the antiobesity effect of CB1 blockade. Indeed,
AM6545 treatment of DIO mice restored leptin suppression of
lipogenic gene expression in fat tissue, which may have con-
tributed to a reduction in adiposity (Tam et al., 2010). However,
leptin sensitivity in the hypothalamus and the mechanism by
which peripheral CB1R blockade may affect it have not been
explored. Here we show that peripheral CB1R inverse agonism
reverses hypothalamic leptin resistance in DIO mice by rapidly
reversing their hyperleptinemia, through decreasing leptin
secretion by adipose tissue and increasing leptin clearance
via the kidney.l Metabolism 16, 167–179, August 8, 2012 ª2012 Elsevier Inc. 167
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Figure 1. JD5037 Is a Peripherally Restricted CB1 Receptor Inverse
Agonist
(A) Structure of JD5037 and its brain-penetrant parent SLV319.
(B) JD5037 has 20 times higher CB1 binding affinity than SLV319 (left), and
both are inverse agonists, as tested by GTPgS binding (right). Each curve
represents the mean of three experiments performed in triplicate.
(C) Brain and plasma levels of JD5037 and SLV319 1 hr following acute or
28 day oral dosing at 3 mg/kg, n = 4–7 animals. Both compounds accumulate
in liver, with hepatic levels after acute versus chronic administration of 3,676 ±
37 versus 6,262 ± 540 ng/g (JD5037) and 817 ± 88 versus 4,384 ± 386 ng/g
(SLV319).
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JD5037 Is a Peripheral CB1R Inverse Agonist Devoid of
Behavioral Effects
To reduce its brain penetrance, we modified the structure of the
CB1R inverse agonist SLV319, yielding the compound JD5037
(Figure 1A). The absolute configuration of JD5037 as the S,S dia-
stereomer was confirmed by X-ray diffraction (see Figure S1A
online). JD5037 has high CB1R binding affinity (Ki 0.35 nM) and
>700-fold CB1/CB2 selectivity. Both SLV319 and JD5037 are
CB1R inverse agonists, verified by GTPgS binding (Figure 1B).
CB1R specificity of JD5037 was confirmed as a potency ratio
of >1,000 relative to a panel of 70 receptors, transporters, and
ion channels (Table S1). Acute oral administration of 3 mg/kg
JD5037 blocked the inhibition of gastrointestinal motility by
a maximally effective dose of anandamide (Figure S1B), indi-
cating full occupancy of CB1R on cholinergic terminals inner-
vating the gut. Drug levels in plasma, brain, and liver were
measured 1 hr after acute or 28 day oral dosing of JD5037 or
SLV319 at 3 mg/kg/day. The brain/plasma ratio of JD5037 was
<2% after acute and 7% after chronic dosing, much lower
than corresponding values for SLV319, and both compounds
accumulated in liver (Figure 1C, legend). Furthermore, nonspe-
cific binding to brain proteins, determined by equilibrium dialysis
using CB1R
/ mouse brain, was 99.7%, resulting in subnano-
molar free concentration of JD5037 in brain. The absence of
in vivo brain CB1R occupancy following acute or chronic admin-
istration of JD5037 was documented by PET, showing lack of
displacement of a CB1R PET ligand when JD5037 was given
either before (Figure 1D) or after the radioligand (Figure 1E). Rela-
tive to SLV319, JD5037 has a larger polar surface area (117
versus 74), hydrogen bonding capacity (3 versus 1), and molec-
ular weight (572 versus 487), limiting brain penetrance. P-glyco-
protein-mediated extrusion of JD5037, indicated by moderately
higher brain levels in Mdr1a/b/ than wild-type mice (Fig-
ure S1C), also contributes to low brain penetrance.
Accordingly, JD5037 was inactive in behavioral paradigms:
unlike SLV319, JD5037 did not increase locomotor activity (Fig-
ure S1D), nor did it inhibit CB1R-mediated catalepsy (Fig-
ure S1E). Neither compound was anxiogenic in the elevated
plus maze, whereas rimonabant was anxiogenic (Figure S1F).
The lack of effect of SLV319 relative to rimonabant reflects
the lower brain penetrance and resulting lower central CB1R
occupancy by the former (Need et al., 2006).
Peripheral CB1R Inverse Agonism Is Fully Effective in
Reducing Food Intake, Body Weight, and Hormonal/
Metabolic Abnormalities in DIO Mice
Male C57Bl/6J kept mice on a diet containing 60% of calories as
fat became obese (body weight >42 g) after 14 weeks. In DIO(D) Pretreatment of mice with SLV319, but not with JD5037 (3 mg/kg p.o. 1 hr
prior to test), results in displacement of PET ligand from brain CB1R. Scans
from typical experiments are shown, with statistics from three to six replicates.
*p < 0.05 relative to values in vehicle pretreated mice.
(E) SLV319, but not JD5037 (3 mg/kg i.v. each), displaces bound CB1 PET
ligand.
For crystallographic structure, physicochemical features, and behavioral
profile of JD5037 see also Figure S1. Vertical bars represent SEM.
.
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Figure 2. SLV319 and JD5037 Cause Similar
Metabolic Effects in DIO Mice
(A) Transient reduction of daily food intake, n = 7
mice/group.
(B) JD5037 does not induce taste aversion,
as tested in lean mice. n = 6–7/group. *p <
0.001 relative to vehicle. #p < 0.01 relative to LiCl
group.
(C and D) (C) SLV319 and JD5037 (3 mg/kg/day for
28 days) normalize body weight and (D) reduce
adiposity. n = 7/group, *p < 0.005 relative to STD,
#p < 0.01 relative to HFD vehicle group.
(E) JD5037 treatment reduces body fat without
affecting lean bodymass, as assessed byMRI. N =
6/group. * and # as in (D).
(F–I) Reversal of HFD-induced steatosis (hepatic
triglycerides) and hepatocellular damage (plasma
ALT, AST). * and # as in (D).
(J–M) Reversal of HFD-induced hyperglycemia,
hyperinsulinemia, glucose intolerance (ipGTT),
and insulin resistance (ipIST). * and # as in (D).
(N and O) Reversal of HFD-induced hyper-
leptinemia and hypoadiponectinemia. * and # as
in (D).
(P and Q) Improved plasma lipid profile, * and # as
in (D).
For additional effects on substrate utilization and
energy expenditure, see Figure S4. Vertical bars
represent SEM.
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Peripheral CB1 Blocker Reverses Leptin Resistancemice treated with oral doses of 3 mg/kg/day for 28 days,
JD5037 and SLV319 caused equal reductions in food intake
(Figure 2A), body weight (Figure 2C), and adiposity (Figure 2D),
with tolerance to the anorexic effect developing after 14 days.
JD5037 was inactive in conditioned taste avoidance tests
(Figure 2B); thus, the reduced food intake is not due to tasteCell Metabolism 16, 167–17aversion. Off-target effects are unlikely,
as JD5037 did not affect food intake
or body weight in CB1R
/ mice (Fig-
ure S2). In contrast to the similar
anorectic effect of global and peripheral
CB1R blockade in unfasted DIO mice,
which indicates a peripheral mechanism,
only SLV319 and not JD5037 was able
to reduce food intake in a fasting/refeed-
ing paradigm tested in lean as well as
ob/ob mice (Figure S3), indicating that
the latter effect is centrally mediated and
leptin independent.
Normalization of body weight was
due to reduction in total body fat with
no change in lean body mass, as deter-
mined by MRI (Figure 2E). The two
compounds were also equieffective in
reversing hepatic steatosis and hepato-
cellular damage (Figures 2F–2I), normal-
izing blood glucose and insulin levels
(Figures 2J and 2K), attenuating glucose
intolerance and insulin resistance (Fig-
ures 2L and 2M), reversing the hyperlepti-nemia and hypoadiponectemia (Figures 2N and 2O), and
improving plasma lipid profile (Figures 2P and 2Q). Indirect calo-
rimetry revealed increased total energy expenditure due to a
selective increase in fat burning, as reflected in a reduction of
the respiratory quotient, with JD5037 being somewhat more
efficacious than SLV319 (Figure S4).9, August 8, 2012 ª2012 Elsevier Inc. 169
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Figure 4. JD5037 Causes Hypophagia and
Weight Loss in DIO Mice via Endogenous
Leptin
(A and B) Pretreatment of DIO mice with a leptin
antagonist (GESLAN, 5 mg/g/day) prevents the
weight loss and hypophagia caused by JD5037,
3mg/kg/day (treatment start at [). *p < 0.05 rela-
tive to GESLAN + vehicle group, n = 5 mice/group.
(C and D) Reversal of HFD-induced hyper-
leptinemia by JD5037, 3 mg/kg/day, but not by
pair feeding, precedes reversal of the weight gain.
*p < 0.05 relative to corresponding vehicle values,
n = 8/group.
(E and F) Positive correlation between reversal of
hyperleptinemia and reduction of either body
weight or daily food intake, as calculated from
data in (B)–(D).
Vertical bars represent SEM.
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JD5037 Are Leptin Dependent
The above effects of JD5037 developed rapidly within 7 days
of treatment of DIO mice (Figure 3, left pair of columns). Simi-
lar 7 day treatment of obese, leptin-deficient ob/ob or leptin
receptor-defective db/db mice caused comparable changes in
metabolic parameters (Figures 3D–3M) but did not affect food
intake, body weight, or adiposity (Figures 3A–3C), suggesting
that changes in the latter reflect resensitization of DIO mice
to endogenous leptin. This was further supported by the
effects of a pegylated superactive leptin antagonist that blocksFigure 3. Metabolic Effects of JD5037 in DIO, ob/ob, and db/db Mice
(A–C) JD5037 (3 mg/kg/day, 7 days) reduces body weight, adiposity, and food intake in DIO but not in ob/ob
mice/group.
(D and E) JD5037 treatment attenuates the hyperglycemia and hyperinsulinemia in DIO, ob/ob, and db/db m
(F and G) JD5037 attenuates the glucose intolerance (ipGTT) and insulin resistance (ipIST) in DIO and ob/o
values.
(H–J) JD5037 reduces hepatic triglycerides, plasma ALT, and AST in all three strains.
(K) JD5037 attenuates hyperleptinemia in DIO and db/db mice, no plasma leptin in ob/ob mice.
(L and M) JD5037 causes similar increases in plasma adiponectin and FFA in DIO, ob/ob, and db/db mice.
For the lack of an acute hypophagic effect of JD5037 in a fasting/refeeding paradigm, see Figure S3, and for t
body weight in CB1R
/ mice, see Figure S2. Vertical bars represent SEM.
Cell Metabolism 16, 167–17the interaction of leptin with its receptor
and, as a result, causes hyperphagia
and body weight gain in lean mice
(Shpilman et al., 2011) but has no such
effects in mice made leptin resistant
by viral overexpression of hypothalamic
leptin (Scarpace et al., 2007). Accord-
ingly, treatment of DIO mice with 5 mg/g
of the leptin antagonist for 5 days did
not affect food intake or body weight
but abolished the weight reduction (Fig-
ure 4A) and hypophagia caused by
JD5037 treatment, started on day 3
(Figure 4B).
As hyperleptinemia is thought to be
responsible for leptin resistance in DIO
(Knight et al., 2010; Scarpace et al.,2002), we tested whether its reversal may restore leptin sensi-
tivity in DIO mice. JD5037 rapidly reversed the hyperleptinemia:
by the third day of treatment, >70% of the diet-induced incre-
ment of plasma leptin was eliminated, whereas only 20% of
the body weight gain was lost. These effects were due to a
direct effect of CB1R blockade on the production and clear-
ance of leptin, because they could not be reproduced by pair
feeding (Figures 4C and 4D). Furthermore, the reversal of
hyperleptinemia significantly and inversely correlated with the
parallel decreases in food intake (Figure 4E) and body weight
(Figure 4F).or db/dbmice. *p < 0.05 relative to vehicle, n = 5–6
ice.
b mice. *p < 0.5 relative to corresponding vehicle
he lack of effect of JD5037 on daily food intake and
9, August 8, 2012 ª2012 Elsevier Inc. 171
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Cell Metabolism
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in DIO Mice
DIO mice are leptin resistant, as illustrated by the loss of leptin-
induced anorexia, weight loss, and STAT3 phosphorylation in the
arcuate nucleus. Chronic oral treatment with JD5037 restored
all three parameters to levels in lean controls (Figures 5A–5C).
The increased hypothalamic level of suppressor of cytokine
signaling-3 (SOCS3), thought to account for reduced STAT3
phosphorylation (Howard and Flier, 2006), was also reversed
(Figures 5D and 5E).
To further test whether reversal of the hyperleptinemia is
sufficient to restore leptin sensitivity, DIO mice were infused
with leptin at different rates for 7 days and simultaneously treated
with daily oral doses of 3mg/kg JD5037 or vehicle. Plasma leptin
was significantly reduced by JD5037, the reduction being pro-
gressively greater the higher the pretreatment level (Figure 5F).
In each leptin dose group, JD5037 treatment fully restored
leptin-induced appetite and weight reduction (Figure 5F) and
increased hypothalamic pSTAT3 (Figure 5G), even though
plasma leptin in themice infusedwith 3 mg/g/day leptin remained
above those in vehicle-treated, saline-infused DIO mice (Fig-
ure 5F). Another group of mice was infused with human leptin,
levels of which were similarly reduced by JD5037 treatment as
assayed using a human-specific ELISA, clearly indicating an
effect on leptin clearance (Figure 5F). These findings indicate
that it is the rapid reduction of plasma leptin rather than its abso-
lute level that is critical in restoring leptin sensitivity.
The islet-derived anorexogenic peptide amylin also reverses
leptin resistance by an action in the area postrema (AP) (Lutz,
2010). Because the AP contains CB1R and lacks a blood-brain
barrier (Suarez et al., 2010), we tested whether it may also be
the site of action of JD5037. In DIO mice with thermal ablation
of the AP (APX), 7 day oral treatment with 3 mg/kg JD5037
caused the same reduction in food intake, body weight, and
adiposity and restored leptin-induced anorexia and weight loss
as in similarly treated sham-operated DIO mice. In contrast,
5 mg/kg amylin reduced food intake in sham-operated but not
in APX DIO mice (Figure S5), as documented earlier (Lutz,
2010). Thus, the AP is not the site of action of JD5037.
Peripheral CB1R Blockade Suppresses Leptin Secretion
Because the reduction of plasma leptin by JD5037 treatment
preceded the weight loss, it couldn’t have simply resulted from
loss of fat mass. Indeed, CB1R blockade reversed the obesity-
related increase in leptin mRNA in adipose tissue, suggesting
a direct effect on leptin gene expression (Figure 6A). Further-
more, 24 hr incubation of differentiated 3T3 L1 adipocytes with
different CB1R agonists increased leptin in the culture medium,Figure 5. Inverse Agonism at Peripheral CB1R Reverses Leptin Resista
(A) Effect of leptin (3 mg/kg twice daily for 4 days) on body weight in lean and
n = 4/group, *p < 0.05 relative to corresponding vehicle-treated group.
(B) Effect of leptin on food intake in the same groups as in (A).
(C) Leptin-induced phosphorylation of hypothalamic STAT3 is suppressed in DIO
28 days, as visualized by western blotting. Means ± SE from six mice per group
(D and E) HFD-induced increase in hypothalamic SOCS3 mRNA and protein is r
(F) Plasma leptin, food intake, and body weight change in DIO mice chronically inf
treated for 7 days with vehicle or JD5037, 3 mg/kg/day. *p < 0.05 relative to veh
(G) JD5037 increases basal pSTAT3 and restores leptin-induced pSTAT3 in DIO
For evidence against the role of the AP in leptin sensitization by CB1 blockade, s
Celwhich was inhibited by 100 nM JD5037 (Figure 6B). Gi protein
involvement was indicated by increased expression of active
Gia (Figure 6C) and by pertussis toxin blockade of CB1R-induced
leptin secretion (Figure 6D).
Leptin increases sympathetic tone, which promotes lipolysis
and lipid oxidation in adipose tissue (Buettner et al., 2008). NE
in adipose tissue was decreased by HFD, and the reduction
was reversed by CB1 blockade (Figure 6E). JD5037 was more
effective than SLV319, suggesting that their target was periph-
eral CB1R on sympathetic terminals innervating fat pads,
blockade of which reverses CB1R-mediated inhibition of NE
release. The reduced b3-adrenergic receptor gene expression
in adipose tissue of DIO mice was also partially reversed by
JD5037 (Figure 6F). The role of increased sympathetic tone in
the reduction of leptin levels by JD5037 treatment was tested
in DIO mice with chemical sympathetic denervation of the
epididymal fat pad by local injection of 6-hydroxydopamine. As
shown in Figure S6, NE was undetectable in the denervated fat
pad of both vehicle- and JD5037-treated DIO mice. In parallel,
JD5037-induced reductions in plasma leptin and body weight
were significantly smaller in mice with denervated versus those
with intact fat pads.
Peripheral CB1R Blockade Increases Leptin Clearance
The reversal of hyperleptinemia by CB1 blockade also involves
increased leptin clearance. The elimination half-life of leptin
was increased 2-fold in DIO mice, which was reversed by
JD5037 treatment (Figure 7A). Leptin is removed by glomerular
filtration followed by metabolic degradation in the renal tubules
(Cumin et al., 1997). The increase in serum creatinine in DIO
mice suggests that leptin removal by glomerular filtration is
reduced in DIO, and reversal of this change by JD5037 (Fig-
ure 7C) implicates CB1R.
The subsequent tubular uptake and metabolism of leptin is
also reduced in DIO and reversed by CB1R blockade. The renal
levels of megalin, a multiligand endocytic receptor that mediates
the tubular uptake of leptin (Ceccarini et al., 2009; Hama et al.,
2004), was reduced by HFD in wild-type but not in CB1
/
mice, and JD5037 increased megalin mRNA and protein levels
in the kidney of DIO mice (Figures 7D–7F). Proper folding and
export of megalin from the endoplasmic reticulum is dependent
on the chaperone, receptor-associated protein (RAP) (Birn et al.,
2000). Renal levels of RAP were also reduced in DIO mice and
normalized by JD5037 treatment (Figure 7F).
Direct evidence for the role of CB1R in megalin-mediated lep-
tin clearance was obtained in cultured renal proximal tubular
epithelial cells (RPTECs), which express CB1R (Jenkin et al.,
2010; Lim et al., 2010). Removing the serum from the culturence
DIO mice and in DIO mice treated for 7 days with JD5037, 3 mg/kg/day p.o.
mice, but not in DIO mice pretreated with JD5037 or SLV379, 3/mg/kg/day for
were analyzed by densitometry.
eversed by chronic JD5037 treatment.
used with saline, 1 or 3 mg/g/day mouse leptin, or 3 mg/g/day human leptin, and
icle.
mice; densitometry as in (C).
ee Figure S5. Vertical bars represent SEM.
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Figure 6. Peripheral CB1R Inverse Agonism
Reduces Leptin Expression and Secretion
by Adipose Tissue
(A) JD5037 or SLV319 (3 mg/kg/day, 28 days)
reverses the HFD-induced increase in adipose
tissue leptin mRNA. *p < 0.05 relative to STD
vehicle, #p < 0.05 relative to HFD-vehicle. n = 6
mice/group.
(B) Activation of CB1R in 3T3 L1 adipocytes
increases leptin secretion. Cells were incubated
for 24 hr with 100 nM noladin ether, 100 nM HU-
210, or 500 nM anandamide in the presence of the
FAAH inhibitor AM3506, 100 nM (Godlewski et al.,
2010), alone or in combination with 100 nM
JD5037. *p < 0.05 relative to agonist alone.
(C) CB1 agonists increase active Gia in 3T3
L1 adipocytes, as quantified by densitometry of
western blots.
(D) Pertussis toxin blocks CB1 agonist-induced
leptin secretion by 3T3 L1 adipocytes.
(E and F) Peripheral CB1 blockade reverses
obesity-induced reduction of adipose tissue NE
content and b3-receptor mRNA. *p < 0.05 relative
to STD, #p < 0.05 relative to HFD vehicle.
For the effect of JD5037 in denervated DIO mice,
see Figure S6. Vertical bars represent SEM.
Cell Metabolism
Peripheral CB1 Blocker Reverses Leptin Resistancemedium reduced the cellular levels of anandamide (Figure 7H),
whereas 125I-leptin uptake was increased (Figure 7I), which par-
alleled the increase inmegalin, RAP, and PPARa, a positive regu-
lator of megalin expression (Cabezas et al., 2011) (Figure 7G).
This suggests that in cells maintained in serum-containing
medium, the higher levels of anandamide tonically inhibit mega-
lin expression and, consequently, leptin degradation. Accord-
ingly, megalin expression, 125I-leptin uptake, and degradation
in such cells were increased by JD5037 in a CB1R agonist-
reversible manner (Figures 7J–7L).
Megalin is present in choroid plexus endothelial cells, where it
has been implicated in leptin transport from blood to CSF (Die-
trich et al., 2008). Interestingly, megalin expression was reduced
by HFD in parallel with a reduced CSF:plasma leptin ratio, and
both changes were reversed by JD5037 treatment (Figure S7).
DISCUSSION
We report that a peripherally restricted CB1R inverse agonist,
JD5037, is equieffective with its brain-penetrant parent com-
pound in decreasing daily food intake, body weight, and174 Cell Metabolism 16, 167–179, August 8, 2012 ª2012 Elsevier Inc.adiposity in DIO mice. This clearly indi-
cates that inverse agonism at peripheral
CB1R rather than a central action medi-
ates these effects, confirming earlier
suggestions that the hypophagic effect
of brain-penetrant CB1 inverse agonists
may be mediated by peripheral CB1R
(Gomez et al., 2002; Need et al., 2006).
The role of leptin in these effects is sup-
ported by their absence in ob/ob and
db/db mice and in DIO mice pretreated
with a leptin antagonist. In contrast, thehunger-induced food intake on refeeding fasted nonobese
mice was suppressed only by SLV319 and not by JD5037, and
SLV319 retained its efficacy in ob/obmice (Figure S3), indicating
that this latter effect is centrally mediated and leptin indepen-
dent, as reported earlier (Di Marzo et al., 2001). However, this
acute effect, which occurs in the first hour after refeeding and
thus reflects meal initiation rather than consummatory food
intake, is unlikely to contribute to weight loss in nonfasted DIO
mice treated with a CB1R inverse agonist. The most likely mech-
anism underlying this latter effect is reversal of the obesity-
related leptin resistance due to a rapid reversal of hyperleptine-
mia, which results from reduced leptin secretion by adipocytes
and increased leptin clearance via the kidneys, as discussed
below. Nevertheless, we can’t exclude the possibility that other
mechanisms may also contribute to the effects of peripheral
CB1R blockade on consummatory food intake and body weight.
The gold standard marker of cellular leptin action is pSTAT3
in the arcuate nucleus (Myers et al., 2010). JD5037 treatment
of DIO mice restored leptin-induced hypothalamic pSTAT3
to levels in lean mice, and also increased basal pSTAT3 (Fig-
ure 5C), suggesting sensitization to endogenous leptin. JD5037
Cell Metabolism
Peripheral CB1 Blocker Reverses Leptin Resistancetreatment also restored the appetite- and weight-reducing
effects of leptin. Because hyperleptinemia is required for leptin
resistance in DIO (Knight et al., 2010), these effects likely resulted
from the rapid reversal of hyperleptinemia. If reversing leptin
resistance reduces obesity, one might also expect that leptin
resistance promotes obesity. Indeed, viral overexpression of
leptin in the hypothalamus induces leptin resistance and exacer-
bates DIO (Scarpace and Zhang, 2007), whereas preventing
leptin resistance may have the opposite effect. In the study of
Knight et al. (2010), mice with maintained leptin sensitivity
achieved the same weight on HFD as wild-type mice that
became leptin resistant. However, their prediet weight was sub-
stantially higher, so they gained less weight despite a trend for
reduced locomotor activity, which suggests partial resistance
to DIO.
Resensitization to leptin by JD5037 was independent of the
degree of hyperleptinemia in DIO mice chronically infused with
leptin (Figures 5F and 5G). This is compatible with the asym-
metric nature of leptin action, whereby a reduction of plasma
leptin in conditions of negative energy balance powerfully stimu-
lates appetite and energy conservation, whereas increased
leptin in states of weight gain is less effective as a counterregula-
tory signal (Leibel, 2008). In this model, leptin resistance mani-
fests as an increase in set point for adipose mass, as reflected
by plasma leptin, below which the anabolic counterregulatory
response is activated to protect body weight (Leibel, 2008).
Accordingly, leptin infusion to DIO mice increased the set point
to higher plasma leptin levels, from which comparable reduc-
tions by JD5037 resulted in similar increases in leptin sensitivity
(Figures 5F and 5G).
Reduction of plasma leptin by JD5037 was the combined
result of decreased leptin expression and secretion by adipo-
cytes and increased leptin clearance. The decrease in leptin
secretion by JD5037 likely involves two mechanisms. First,
differentiated adipocytes express CB1R (Bensaid et al., 2003;
Cota et al., 2003), which may regulate leptin expression and
secretion. Indeed, JD5037 reduced ob mRNA in adipose tissue
in vivo and reversed CB1R-mediated increases in leptin secre-
tion in adipocytes in vitro (Figures 6A and 6B). Second, inhibition
of NE release by presynaptic CB1R can be removed by pharma-
cological blockade (Ishac et al., 1996) or genetic deletion of
CB1R in sympathetic neurons (Quarta et al., 2010), and the re-
sulting increase in sympathetic tone accounts for the increased
NE content of adipose tissue of JD5037-treated DIO mice (Fig-
ure 6E). JD5037 also increased b3-adrenergic receptor expres-
sion, and NE acting via b3-receptors in adipocytes suppresses
leptin secretion (Gettys et al., 1996; Mantzoros et al., 1996).
Furthermore, peripheral CB1R blockade resensitizes DIO mice
to leptin, and leptin itself increases sympathetic tone through
a central action (Buettner et al., 2008). Both of these mecha-
nisms could contribute to the increased NE levels in fat pads
of JD5037-treated DIO mice, which reflects reversal of the
well-established decrease of sympathetic tone in DIO (Cru-
ciani-Guglielmacci et al., 2005). Finally, the increased sympa-
thetic tone to adipose tissue also mediates the increased
energy expenditure of JD5037-treated DIO mice (Figure S4) by
increasing lipolysis and fatty acid oxidation via adipocyte
b-adrenergic receptors (Bachman et al., 2002; Song et al.,
2010). Thus, blockade of CB1R on adipocytes and on sympa-Celthetic nerve terminals innervating fat pads may both contribute
to reduced leptin secretion.
As to the relative contribution of these two mechanisms, the
role of presynaptic CB1R on sympathetic nerves is indicated
by our finding that chemical denervation of the major visceral
fat pad in DIO mice significantly attenuated JD5037-induced
reductions in plasma leptin and body weight (Figure S6). In
turn, the role of adipocyte CB1R is supported by the observed
effects of CB1R ligands in cultured adipocytes (Figure 6B). Addi-
tional in vivo evidence may be obtained in mice with selective
deletion of CB1R in adipocytes (Mancini et al., 2010).
The slower rate of leptin elimination in DIO mice (Figure 7A) is
similar to that in obese humans (Wong et al., 2004), which
contributes to hyperleptinemia. In turn, reversal of hyperleptine-
mia by CB1R blockade involves increased leptin clearance (Fig-
ure 7A). Leptin is removed by glomerular filtration followed by
metabolic degradation in the proximal tubules via uptake by
the multifunctional endocytic receptor megalin (Ceccarini et al.,
2009). Here we report that CB1R receptors in RPTECs regulate
megalin expression and leptin uptake and degradation. First,
primary-cultured, serum-stimulated RPTECs generate ananda-
mide and express CB1R (Figures 7G and 7H), blockade of which
increases megalin expression as well as leptin uptake and
degradation (Figures 7J–7L). Second, DIO mice have reduced
renal megalin and RAP levels, which are normalized by JD5037
(Figures 7D–7F).
Despite its reduced tubular uptake andmetabolism, only trace
amounts of leptin are present in the urine of DIOmice (Figure 7B).
This suggests that reduced amounts of leptin reach the tubules
by filtration, and/or unmetabolized leptin may be reabsorbed
into the circulation. As for leptin filtration, CB1R are present in
glomerular podocytes, where their overexpression promotes
apoptosis (Barutta et al., 2010), and in arterioles, where their
stimulation reduces glomerular filtration rate (Koura et al.,
2004). Glomerular filtration is also reduced in obese Zucker
rats and normalized by chronic rimonabant treatment (Janiak
et al., 2007). In the present study, JD5037 treatment normalized
the elevated plasma creatinine of DIOmice (Figure 7C), suggest-
ing improved glomerular filtration. Furthermore, renal fractional
extraction of leptin is reduced in hyperleptinemia (Meyer et al.,
1997), and it may also be reversed by CB1R blockade.
Additionally, at low tubular levels of megalin, intact leptin may
be reabsorbed into the circulation contributing to the hyperlepti-
nemia, and CB1 blockade would limit such transcytosis by
restoring megalin-mediated leptin degradation. Indeed, in polar-
ized cells, such as RPTECs, leptin transport in apical to basolat-
eral direction can occur via the short form of the leptin receptor
(ObRa) (Hileman et al., 2000), which is highly expressed in the
kidney (Fei et al., 1997).
Megalin is present in the choroid plexus epithelium, which also
expresses CB1R (Maccarrone et al., 2006), providing another
mechanism by which CB1 ligands could modulate a peripheral
form of leptin resistance. The parallel reductions of megalin in
the choroid plexus and of the CSF:plasma ratio of leptin, and
their reversal by chronic JD5037 treatment (Figure S6), are
compatible with such a mechanism.
As to alternativemechanisms for leptin sensitization by periph-
eral CB1 blockade, the possible role of the AP, a brain structure
with defective blood-brain barrier and the site of action of thel Metabolism 16, 167–179, August 8, 2012 ª2012 Elsevier Inc. 175
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Figure 7. Reduced Leptin Clearance in DIO Mice Is Normalized by Peripheral CB1 Blockade
(A) Pharmacokinetics of human leptin (10mg/kg i.p.) injected into lean (STD-veh, t1/2 33.5 ± 0.1min) and DIOmice (HFD-veh, t1/2 50.2 ± 4.8min, p < 0.05) and DIO
mice treated with JD5037, 3 mg/kg/day p.o. for 7 days (t1/2 28.8 ± 0.9 min). Note that the increase in t1/2 in DIO mice is reversed by JD5037, *p < 0.05 relative to
STD, #p < 0.05 relative to HFD vehicle.
(B) Leptin microuria in DIO mice is reversed by JD5037 treatment, * and # as in (A).
(C) JD5037 reverses the diet-induced increase in serum creatinine levels, * and # as in (A).
(D) Reduction in megalin mRNA in kidney of DIO mice is reversed by JD5037 treatment.
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Peripheral CB1 Blocker Reverses Leptin Resistanceleptin-sensitizing peptide amylin (Lutz, 2010) could be ruled out
(see Figure S5). The proposed role of afferent nerve terminals
in the gut in the anorectic and weight-reducing effects of CB1
blockade (Gomez et al., 2002) is also unlikely, because sub-
diaphragmatic vagal deafferentation or complete celiac/superior
mesenteric gangliectomy had no effect on the hypophagic
response of rodents to rimonabant (Madsen et al., 2009).
Mice with selective genetic deletion (Quarta et al., 2010) or
desensitization of CB1R (Jung et al., 2012) in CaMKIIa-contain-
ing neurons are lean and resistant to DIO, similar to mice with
global CB1R knockout. Because CaMKIIa is expressed predom-
inantly (although not exclusively) in the brain, these findings
suggest that CB1R in the CNS are required for the development
of DIO. This does not negate the role of peripheral CB1R in
maintaining or reversing obesity, as obesity upregulates CB1R
in fat tissue (Bensaid et al., 2003), liver (Jourdan et al., 2010;
Osei-Hyiaman et al., 2008; Quarta et al., 2010), and skeletal
muscle (Pagotto et al., 2006), and CB1R blockade reduces
body weight in obese but not in lean mice (Jbilo et al., 2005).
A key finding of the present study is the greater efficacy of
peripheral CB1R inverse agonism compared to neutral antago-
nism in reducing food intake and body weight. Hyperleptinemia,
which is the target of these effects, was partially reduced by the
neutral antagonist AM6545 (Tam et al., 2010) but completely
normalized by JD5037 (Figure 2N). It is possible that in obesity
the fraction of CB1R present in the active conformation is
increased in peripheral tissues involved in metabolic regulation,
which could account for the greater efficacy of inverse agonists
over neutral antagonists.
JD5037-induced hypophagia and weight loss were absent in
ob/ob and db/db mice and in DIO mice treated with a leptin
antagonist, indicating the role of leptin in these effects. In
contrast, JD5037 caused comparable improvements in glucose
tolerance and insulin sensitivity in all three strains of mice,
thus these effects are leptin independent. Diet-induced hepatic
insulin resistance is mediated by hepatic CB1R (Liu et al.,
2012; Osei-Hyiaman et al., 2008), and CB1 agonists induce
muscle insulin resistance in lean mice, reversible by CB1
blockade (Song et al., 2011). Thus, the insulin-sensitizing effect
of JD5037 is likely mediated via CB1R in liver and skeletal
muscle.
In summary, peripherally restricted CB1R inverse agonists
have therapeutic potential in obesity. Their high efficacy in
normalizing the relatedmetabolic abnormalities, including insulin
resistance and fatty liver, would warrant their testing as mono-
therapy in these conditions. A key component in the mode of
action of CB1R inverse agonism is reversal of leptin resistance,
as illustrated in the graphical abstract. An important issue in
obesity treatment is inability to maintain weight loss, due to the
perception by the brain of weight loss as a relative leptin-defi-(E) HFD reduces renal megalin protein in wild-type but not in CB1
/ mice (dens
CB1
/-STD.
(F) Reduced megalin and RAP protein in the DIO kidney are normalized by JD50
(G–I) Switching RPTEC from regular (RM) to serum-free medium (SF) increase
increases leptin uptake.
(J–L) In RPTEC maintained in regular medium, JD5037 (1 mM, 24 hr) increases me
coincubation with 100 nM HU-210. *p < 0.05 relative to vehicle, #p < 0.05 relativ
For CB1/megalin interaction in the choroid plexus, see Figure S7. Vertical bars re
Celcient state, which triggers an anabolic response promoting the
regain of lost weight (Rosenbaum and Leibel, 2010). Thus, by
sensitizing the body to endogenous leptin, peripheral CB1R
blockade may not only promote weight loss, but could help
maintain it.
EXPERIMENTAL PROCEDURES
Drugs
JD5037, a structurally modified analog of SLV319 (ibipinabant), was synthe-
sized and its diastereomeric structure verified by X-ray crystallography, as
detailed in the Supplemental Experimental Procedures.
Experimental Protocol
Six-week-old male C57Bl/6J mice received a diet containing 60% of calories
as fat, resulting in body weights >42 g in 12–14 weeks. Mice with DIO then
received vehicle, JD5037, or SLV319 daily for 7–28 days by oral gavage of
3 mg/kg. Age-matched control mice on standard diet (STD) received vehicle
daily. Body weight and food intake were monitored daily. At the end of the
treatment period, groups of mice were subjected to i.p. glucose tolerance
and insulin sensitivity tests or indirect calorimetry. Mice were then sacrificed
by cervical dislocation, and total body fat content and lean mass were deter-
mined by MRI. In other mice the brain, liver, kidney, and combined fat pads
were removed, weighed, and snap frozen, and trunk blood was collected for
determining endocrine and biochemical parameters. Adiposity index was
defined as the combined weight of the epidydimal, retroperitoneal, and
inguinal fat pads, expressed as percentage of total body weight. Adult male
ob/ob and db/db mice were treated with JD5037 or vehicle for 7 days, during
which food intake and body weight had been monitored. Hormonal and meta-
bolic parameters were determined as in mice with DIO.
Leptin Sensitivity
Leptin sensitivity was assessed in two paradigms: (1) STAT3 phosphorylation
in the hypothalamus in response to acute in vivo leptin treatment was quanti-
fied ex vivo by western blotting; (2) reductions in food intake and body weight
in response to subacute leptin treatment were monitored in vivo.
Leptin Clearance
Recombinant human leptin (R&D Systems) was injected i.p. at a dose of
10 mg/kg to mice fed STD or HFD for 14 weeks, or to HFD-fed mice treated
with JD5037 (3 mg/kg p.o.) for 7 days. Blood samples were taken from the
mandibular vein at 60, 180, 300, 360, 420, and 480 min. Serum was immedi-
ately separated, and human leptin level was determined by ELISA (Millipore
Corporation). Terminal elimination rate constant was determined by linear
regression of the last three measurable concentrations and the terminal half-
life of leptin calculated as described (Wong et al., 2004).
Statistical Analyses
Values are expressed as mean ± SEM. Unpaired two-tailed Student’s t test
was used to determine differences between vehicle- and drug-treated groups.
Time-dependent variables were analyzed and results in multiple groups were
compared by ANOVA followed by Bonferroni test. Nonlinear regression anal-
ysis was used to determine the Ki values of ligands in binding assays (Graph-
Pad Prism version 5 for windows). Significance was at p < 0.05.
All animal experiments have been approved by the Animal Care and Use
Committee of NIAAA.itometry of western blots). *p < 0.05 relative to WT-STD, #p < 0.05 relative to
37, 3 mg/kg/day for 28 days, as quantified by densitometry * and # as in (A).
s megalin, RAP, and PPARa expression; reduces anandamide content; and
galin protein levels, leptin uptake, and leptin degradation, effects reversed by
e to JD5037.
present SEM.
l Metabolism 16, 167–179, August 8, 2012 ª2012 Elsevier Inc. 177
Cell Metabolism
Peripheral CB1 Blocker Reverses Leptin ResistanceSUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.07.002.
ACKNOWLEDGMENTS
This work was supported by intramural funds from the National Institute on
Alcohol Abuse and Alcoholism, NIH. Design and synthesis of JD5037 was
funded by Jenrin Discovery, Inc. J.F.M. and R.J.C. hold a patent on JD5037.
We thank V. Pike and C. Morris for support and advice with the PET studies,
and M. Allen, R. Schwartzbeck, A. Noguchi, D. Springer, and R. Kechrid for
their assistance with the animal studies.
Received: January 31, 2012
Revised: April 16, 2012
Accepted: July 6, 2012
Published online: July 26, 2012
REFERENCES
Addy, C., Wright, H., Van Laere, K., Gantz, I., Erondu, N., Musser, B.J., Lu, K.,
Yuan, J., Sanabria-Bohorquez, S.M., Stoch, A., et al. (2008). The acyclic CB1R
inverse agonist taranabant mediates weight loss by increasing energy expen-
diture and decreasing caloric intake. Cell Metab. 7, 68–78.
Bachman, E.S., Dhillon, H., Zhang, C.Y., Cinti, S., Bianco, A.C., Kobilka, B.K.,
and Lowell, B.B. (2002). BetaAR signaling required for diet-induced thermo-
genesis and obesity resistance. Science 297, 843–845.
Barutta, F., Corbelli, A., Mastrocola, R., Gambino, R., Di Marzo, V., Pinach, S.,
Rastaldi, M.P., Perin, P.C., and Gruden, G. (2010). Cannabinoid receptor 1
blockade ameliorates albuminuria in experimental diabetic nephropathy.
Diabetes 59, 1046–1054.
Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J.P., Le Fur, G., Oury-
Donat, F., and Soubrie, P. (2003). The cannabinoid CB1 receptor antagonist
SR141716 increases Acrp30 mRNA expression in adipose tissue of obese
fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908–914.
Birn, H., Vorum, H., Verroust, P.J., Moestrup, S.K., and Christensen, E.I.
(2000). Receptor-associated protein is important for normal processing of
megalin in kidney proximal tubules. J. Am. Soc. Nephrol. 11, 191–202.
Buettner, C., Muse, E.D., Cheng, A., Chen, L., Scherer, T., Pocai, A., Su, K.,
Cheng, B., Li, X., Harvey-White, J., et al. (2008). Leptin controls adipose tissue
lipogenesis via central, STAT3-independent mechanisms. Nat. Med. 14,
667–675.
Cabezas, F., Lagos, J., Cespedes, C., Vio, C.P., Bronfman, M., and Marzolo,
M.P. (2011). Megalin/LRP2 expression is induced by peroxisome prolifera-
tor-activated receptor -alpha and -gamma: implications for PPARs’ roles in
renal function. PLoS ONE 6, e16794. http://dx.doi.org/10.1371/journal.pone.
0016794.
Ceccarini, G., Flavell, R.R., Butelman, E.R., Synan, M., Willnow, T.E., Bar-
Dagan, M., Goldsmith, S.J., Kreek, M.J., Kothari, P., Vallabhajosula, S., et al.
(2009). PET imaging of leptin biodistribution and metabolism in rodents and
primates. Cell Metab. 10, 148–159.
Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert,
M., Auer, D., Yassouridis, A., Thone-Reineke, C., Ortmann, S., et al. (2003). The
endogenous cannabinoid system affects energy balance via central orexigenic
drive and peripheral lipogenesis. J. Clin. Invest. 112, 423–431.
Cruciani-Guglielmacci, C., Vincent-Lamon, M., Rouch, C., Orosco, M., Ktorza,
A., and Magnan, C. (2005). Early changes in insulin secretion and action
induced by high-fat diet are related to a decreased sympathetic tone. Am. J.
Physiol. Endocrinol. Metab. 288, E148–E154.
Cumin, F., Baum, H.P., and Levens, N. (1997). Mechanism of leptin removal
from the circulation by the kidney. J. Endocrinol. 155, 577–585.
Dardeno, T.A., Chou, S.H., Moon, H.S., Chamberland, J.P., Fiorenza, C.G.,
and Mantzoros, C.S. (2010). Leptin in human physiology and therapeutics.
Front. Neuroendocrinol. 31, 377–393.178 Cell Metabolism 16, 167–179, August 8, 2012 ª2012 Elsevier IncDespres, J.P., Golay, A., and Sjostrom, L. (2005). Effects of rimonabant on
metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J.
Med. 353, 2121–2134.
Dietrich, M.O., Spuch, C., Antequera, D., Rodal, I., de Yebenes, J.G., Molina,
J.A., Bermejo, F., and Carro, E. (2008). Megalin mediates the transport of leptin
across the blood-CSF barrier. Neurobiol. Aging 29, 902–912.
Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F.,
Miura, G.I., Palmiter, R.D., Sugiura, T., and Kunos, G. (2001). Leptin-regulated
endocannabinoids are involved in maintaining food intake. Nature 410,
822–825.
Eckardt, K., Sell, H., Taube, A., Koenen, M., Platzbecker, B., Cramer, A.,
Horrighs, A., Lehtonen, M., Tennagels, N., and Eckel, J. (2009). Cannabinoid
type 1 receptors in human skeletal muscle cells participate in the negative
crosstalk between fat and muscle. Diabetologia 52, 664–674.
Enriori, P.J., Evans, A.E., Sinnayah, P., Jobst, E.E., Tonelli-Lemos, L., Billes,
S.K., Glavas, M.M., Grayson, B.E., Perello, M., Nillni, E.A., et al. (2007). Diet-
induced obesity causes severe but reversible leptin resistance in arcuate mel-
anocortin neurons. Cell Metab. 5, 181–194.
Fei, H., Okano, H.J., Li, C., Lee, G.H., Zhao, C., Darnell, R., and Friedman, J.M.
(1997). Anatomic localization of alternatively spliced leptin receptors (Ob-R) in
mouse brain and other tisssues. Proc. Natl. Acad. Sci. USA 94, 7001–7005.
Gettys, T.W., Harkness, P.J., and Watson, P.M. (1996). The beta 3-adrenergic
receptor inhibits insulin-stimulated leptin secretion from isolated rat adipo-
cytes. Endocrinology 137, 4054–4057.
Godlewski, G., Alapafuja, S.O., Batkai, S., Nikas, S.P., Cinar, R., Offertaler, L.,
Osei-Hyiaman, D., Liu, J., Mukhopadhyay, B., Harvey-White, J., et al. (2010).
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in
hypertension without adverse metabolic effects. Chem. Biol. 17, 1256–1266.
Gomez, R., Navarro, M., Ferrer, B., Trigo, J.M., Bilbao, A., Del Arco, I.,
Cippitelli, A., Nava, F., Piomelli, D., and Rodriguez de Fonseca, F. (2002). A
peripheral mechanism for CB1 cannabinoid receptor-dependent modulation
of feeding. J. Neurosci. 22, 9612–9617.
Hama, H., Saito, A., Takeda, T., Tanuma, A., Xie, Y., Sato, K., Kazama, J.J.,
and Gejyo, F. (2004). Evidence indicating that renal tubular metabolism of lep-
tin is mediated by megalin but not by the leptin receptors. Endocrinology 145,
3935–3940.
Hileman, S.M., Tornoe, J., Flier, J.S., and Bjorbaek, C. (2000). Transcellular
transport of leptin by the short leptin receptor isoform ObRa in Madin-Darby
canine kidney cells. Endocrinology 141, 1955–1961.
Howard, J.K., and Flier, J.S. (2006). Attenuation of leptin and insulin signaling
by SOCS proteins. Trends Endocrinol. Metab. 17, 365–371.
Ishac, E.J., Jiang, L., Lake, K.D., Varga, K., Abood, M.E., and Kunos, G. (1996).
Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1
receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118, 2023–
2028.
Janiak, P., Poirier, B., Bidouard, J.P., Cadrouvele, C., Pierre, F., Gouraud, L.,
Barbosa, I., Dedio, J., Maffrand, J.P., Le Fur, G., et al. (2007). Blockade of
cannabinoid CB1 receptors improves renal function, metabolic profile, and
increased survival of obese Zucker rats. Kidney Int. 72, 1345–1357.
Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes, E., Peleraux, A.,
Penarier, G., Soubrie, P., Le Fur, G., Galiegue, S., and Casellas, P. (2005).
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity
phenotype through the regulation of lipolysis and energy balance. FASEB J.
19, 1567–1569.
Jenkin, K.A., McAinch, A.J., Grinfeld, E., and Hryciw, D.H. (2010). Role for
cannabinoid receptors in human proximal tubular hypertrophy. Cell. Physiol.
Biochem. 26, 879–886.
Jourdan, T., Djaouti, L., Demizieux, L., Gresti, J., Verges, B., and Degrace, P.
(2010). CB1 antagonism exerts specific molecular effects on visceral and
subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
Diabetes 59, 926–934.
Jung, K.M., Clapper, J.R., Fu, J., D’Agostino, G., Guijarro, A., Thongkham, D.,
Avanesian, A., Astarita, G., DiPatrizio, N.V., Frontini, A., et al. (2012)..
Cell Metabolism
Peripheral CB1 Blocker Reverses Leptin Resistance2-arachidonoylglycerol signaling in forebrain regulates systemic energy
metabolism. Cell Metab. 15, 299–310.
Knight, Z.A., Hannan, K.S., Greenberg, M.L., and Friedman, J.M. (2010).
Hyperleptinemia is required for the development of leptin resistance. PLoS
ONE 5, e11376. http://dx.doi.org/10.1371/journal.pone.0011376.
Koura, Y., Ichihara, A., Tada, Y., Kaneshiro, Y., Okada, H., Temm, C.J.,
Hayashi, M., and Saruta, T. (2004). Anandamide decreases glomerular filtra-
tion rate through predominant vasodilation of efferent arterioles in rat kidneys.
J. Am. Soc. Nephrol. 15, 1488–1494.
Leibel, R.L. (2008). Molecular physiology of weight regulation in mice and
humans. Int. J. Obes. (Lond.) 32 (Suppl 7 ), S98–S108.
Lim, J.C., Lim, S.K., Han, H.J., and Park, S.H. (2010). Cannabinoid receptor 1
mediates palmitic acid-induced apoptosis via endoplasmic reticulum stress in
human renal proximal tubular cells. J. Cell. Physiol. 225, 654–663.
Liu, J., Zhou, L., Xiong, K., Godlewski, G., Mukhopadhyay, B., Tam, J., Yin, S.,
Gao, P., Shan, X., Pickel, J., et al. (2012). Hepatic cannabinoid receptor-1
mediates diet-induced insulin resistance via inhibition of insulin signaling
and clearance in mice. Gastroenterology 142, 1218–1228.
Lutz, T.A. (2010). The role of amylin in the control of energy homeostasis. Am.
J. Physiol. Regul. Integr. Comp. Physiol. 298, R1475–R1484.
Maccarrone, M., Fiori, A., Bari, M., Granata, F., Gasperi, V., De Stefano, M.E.,
Finazzi-Agro, A., and Strom, R. (2006). Regulation by cannabinoid receptors of
anandamide transport across the blood-brain barrier and through other endo-
thelial cells. Thromb. Haemost. 95, 117–127.
Madsen, A.N., Jelsing, J., van de Wall, E.H., Vrang, N., Larsen, P.J., and
Schwartz, G.J. (2009). Rimonabant induced anorexia in rodents is not medi-
ated by vagal or sympathetic gut afferents. Neurosci. Lett. 449, 20–23.
Mancini, G., Quarta, C., Srivastava, R.K., Klaus, S., Pagotto, U., and Lutz, B.
(2010). Adipocyte-specific CB1 conditional knock-out mice: new insights
in the study of obesity and metabolic syndrome. In 20th Annual Symposium
on the Cannabinoids (Research Triangle Park, NC, USA: International
Cannabinoid Research Society), p. 17.
Mantzoros, C.S., Qu, D., Frederich, R.C., Susulic, V.S., Lowell, B.B., Maratos-
Flier, E., and Flier, J.S. (1996). Activation of beta(3) adrenergic receptors
suppresses leptin expression and mediates a leptin-independent inhibition
of food intake in mice. Diabetes 45, 909–914.
Matias, I., Gonthier, M.P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino,
C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006). Regulation,
function, and dysregulation of endocannabinoids in models of adipose and
beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol.
Metab. 91, 3171–3180.
Meyer, C., Robson, D., Rackovsky, N., Nadkarni, V., andGerich, J. (1997). Role
of the kidney in human leptin metabolism. Am. J. Physiol. 273, E903–E907.
Myers, M.G., Jr., Leibel, R.L., Seeley, R.J., and Schwartz, M.W. (2010). Obesity
and leptin resistance: distinguishing cause from effect. Trends Endocrinol.
Metab. 21, 643–651.
Need, A.B., Davis, R.J., Alexander-Chacko, J.T., Eastwood, B., Chernet, E.,
Phebus, L.A., Sindelar, D.K., and Nomikos, G.G. (2006). The relationship of
in vivo central CB1 receptor occupancy to changes in cortical monoamine
release and feeding elicited by CB1 receptor antagonists in rats.
Psychopharmacology (Berl.) 184, 26–35.
Osei-Hyiaman, D., DePetrillo, M., Pacher, P., Liu, J., Radaeva, S., Batkai, S.,
Harvey-White, J., Mackie, K., Offertaler, L., Wang, L., and Kunos, G. (2005).
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid
synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115, 1298–
1305.
Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong,
W.I., Batkai, S., Marsicano, G., Lutz, B., Buettner, C., and Kunos, G. (2008).
Hepatic CB(1) receptor is required for development of diet-induced steatosis,Celdyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest. 118,
3160–3169.
Pacher, P., Batkai, S., and Kunos, G. (2006). The endocannabinoid system as
an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389–462.
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., and Pasquali, R. (2006). The
emerging role of the endocannabinoid system in endocrine regulation and
energy balance. Endocr. Rev. 27, 73–100.
Quarta, C., Bellocchio, L., Mancini, G., Mazza, R., Cervino, C., Braulke, L.J.,
Fekete, C., Latorre, R., Nanni, C., Bucci, M., et al. (2010). CB(1) signaling in
forebrain and sympathetic neurons is a key determinant of endocannabinoid
actions on energy balance. Cell Metab. 11, 273–285.
Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P.,
Maffrand, J.P., and Soubrie, P. (2003). Anti-obesity effect of SR141716,
a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 284, R345–R353.
Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., and Soubrie, P. (2004).
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to
diet-induced obesity and enhanced leptin sensitivity. Int. J. Obes. Relat.
Metab. Disord. 28, 640–648.
Rosenbaum, M., and Leibel, R.L. (2010). Adaptive thermogenesis in humans.
Int. J. Obes. (Lond.) 34 (Suppl 1 ), S47–S55.
Ruby, M.A., Nomura, D.K., Hudak, C.S., Mangravite, L.M., Chiu, S., Casida,
J.E., and Krauss, R.M. (2008). Overactive endocannabinoid signaling impairs
apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc.
Natl. Acad. Sci. USA 105, 14561–14566.
Scarpace, P.J., and Zhang, Y. (2007). Elevated leptin: consequence or cause
of obesity? Front. Biosci. 12, 3531–3544.
Scarpace, P.J., Matheny, M., Zhang, Y., Shek, E.W., Prima, V., Zolotukhin, S.,
and Tumer, N. (2002). Leptin-induced leptin resistance reveals separate roles
for the anorexic and thermogenic responses in weight maintenance.
Endocrinology 143, 3026–3035.
Scarpace, P.J., Matheny, M., Zhang, Y., Cheng, K.Y., and Tumer, N. (2007).
Leptin antagonist reveals an uncoupling between leptin receptor signal trans-
ducer and activator of transcription 3 signaling and metabolic responses with
central leptin resistance. J. Pharmacol. Exp. Ther. 320, 706–712.
Shpilman, M., Niv-Spector, L., Katz, M., Varol, C., Solomon, G., Ayalon-Soffer,
M., Boder, E., Halpern, Z., Elinav, E., and Gertler, A. (2011). Development and
characterization of high affinity leptins and leptin antagonists. J. Biol. Chem.
286, 4429–4442.
Song, Y., Altarejos, J., Goodarzi, M.O., Inoue, H., Guo, X., Berdeaux, R., Kim,
J.H., Goode, J., Igata, M., Paz, J.C., et al. (2010). CRTC3 links catecholamine
signalling to energy balance. Nature 468, 933–939.
Song, D., Bandsma, R.H., Xiao, C., Xi, L., Shao, W., Jin, T., and Lewis, G.F.
(2011). Acute cannabinoid receptor type 1 (CB1R) modulation influences
insulin sensitivity by an effect outside the central nervous system in mice.
Diabetologia 54, 1181–1189.
Suarez, J., Romero-Zerbo, S.Y., Rivera, P., Bermudez-Silva, F.J., Perez, J., De
Fonseca, F.R., and Fernandez-Llebrez, P. (2010). Endocannabinoid system in
the adult rat circumventricular areas: an immunohistochemical study.
J. Comp. Neurol. 518, 3065–3085.
Tam, J., Vemuri, V.K., Liu, J., Batkai, S., Mukhopadhyay, B., Godlewski, G.,
Osei-Hyiaman, D., Ohnuma, S., Ambudkar, S.V., Pickel, J., et al. (2010).
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic
risk in mouse models of obesity. J. Clin. Invest. 120, 2953–2966.
Wong, S.L., DePaoli, A.M., Lee, J.H., and Mantzoros, C.S. (2004). Leptin
hormonal kinetics in the fed state: effects of adiposity, age, and gender on
endogenous leptin production and clearance rates. J. Clin. Endocrinol.
Metab. 89, 2672–2677.l Metabolism 16, 167–179, August 8, 2012 ª2012 Elsevier Inc. 179
